We are live on ! Find out more
KAM

Krensavage Asset Management Portfolio holdings

AUM $263M
1-Year Est. Return 66.99%
This Fund
S&P 500
This Quarter Est. Return
-11.06%
1 Year Est. Return
+66.99%
3 Year Est. Return
+124.17%
5 Year Est. Return
+196.97%
10 Year Est. Return
+511.9%
AUM
$276M
AUM Growth
+$11.1M
Cap. Flow
+$51.5M
Cap. Flow %
18.64%
Top 10 Hldgs %
70.09%
Holding
23
New
1
Increased
19
Reduced
2
Closed
–

Top Buys

Rank Stock Value
1
BXLT
BAXALTA INC COM STK (DE)
BXLT
+$24.9M
2
UTHR icon
United Therapeutics
UTHR
+$8.13M
3
AMGN icon
Amgen
AMGN
+$5.43M
4
TEVA icon
Teva Pharmaceutical Industries Limited
TEVA
+$4.09M
5
AVNS
Avanos Medical
AVNS
+$3.48M

Top Sells

Rank Stock Value
1
SCMP
Sucampo Pharmaceuticals, Inc.
SCMP
+$10.1M
2
JNP
Juniper Pharmaceuticals, Inc. Common Stock
JNP
+$529K

Sector Composition

Rank Sector Weight
1 Healthcare 93.95%
2 Miscellaneous 6.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ENTA icon
1
Enanta Pharmaceuticals
ENTA
$358M
$26.4M 9.55%
730,308
+23,400
+3% +$1M
UTHR icon
2
United Therapeutics
UTHR
$21.5B
$26.2M 9.48%
199,573
+50,715
+34% +$8.13M
BXLT
3
DELISTED
BAXALTA INC COM STK (DE)
BXLT
$22.7M 8.23%
+721,800
New +$24.9M
TEVA icon
4
Teva Pharmaceutical Industries Limited
TEVA
$45.8B
$21.1M 7.62%
373,062
+63,100
+20% +$4.09M
OFIX icon
5
Orthofix Medical
OFIX
$370M
$20.6M 7.46%
610,247
+86,800
+17% +$3.09M
IPXL
6
DELISTED
Impax Laboratories, Inc.
IPXL
$18.7M 6.77%
530,875
+75,400
+17% +$3.4M
AVNS
7
DELISTED
Avanos Medical
AVNS
$15.2M 5.52%
535,943
+99,700
+23% +$3.48M
AMGN icon
8
Amgen
AMGN
$203B
$14.3M 5.18%
103,536
+34,450
+50% +$5.43M
CNMD icon
9
CONMED
CNMD
$1.41B
$13.1M 4.74%
274,528
+9,100
+3% +$500K
MRK icon
10
Merck
MRK
$355B
$12.3M 4.46%
261,479
+28,715
+12% +$1.53M
HRC
11
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
$10.7M 3.87%
205,713
+6,600
+3% +$357K
SCMP
12
DELISTED
Sucampo Pharmaceuticals, Inc.
SCMP
$10.5M 3.8%
528,175
-439,229
-45% -$10.1M
SRGA
13
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
$10.4M 3.76%
60,956
+1,954
+3% +$374K
ASRT
14
DELISTED
Assertio
ASRT
$7.08M 2.56%
6,256
+208
+3% +$355K
AGN
15
DELISTED
Allergan plc
AGN
$6.59M 2.39%
24,240
+950
+4% +$292K
SPPI
16
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$6.45M 2.33%
1,078,502
+234,800
+28% +$1.63M
IVC
17
DELISTED
Invacare Corporation
IVC
$5.82M 2.11%
402,382
+48,750
+14% +$853K
VXRT
18
DELISTED
Vaxart
VXRT
$5.09M 1.84%
233,689
+84,735
+57% +$2.06M
JNP
19
DELISTED
Juniper Pharmaceuticals, Inc. Common Stock
JNP
$3.29M 1.19%
279,717
-47,900
-15% -$529K
STRR
20
DELISTED
Star Equity Holdings
STRR
$1.71M 0.62%
9,154
+292
+3% +$58.8K
FURX
21
DELISTED
FURIEX PHARMACEUTICALS INC COM STK (DE)
FURX
$1.42M 0.51%
145,544
– –
INVA icon
22
Innoviva
INVA
$1.51B
$1.26M 0.46%
176,108
+5,800
+3% +$78.8K

Similar funds

HWMC
Heritage Wealth Management (California) San Diego, California $263M AUM 22.84% 1-Year Est. Return
IAG
Investmark Advisory Group Shelton, Connecticut $263M AUM 23.11% 1-Year Est. Return
VC
VarCov Co Darien, Connecticut $263M AUM
AIA
Alternative Investment Advisors Maitland, Florida $263M AUM 23.63% 1-Year Est. Return
CCM
Cambridge Capital Management O'fallon, Illinois $263M AUM 18.92% 1-Year Est. Return
HP
Haven Private Orlando, Florida $263M AUM 21.06% 1-Year Est. Return
BCM
Birmingham Capital Management Birmingham, Alabama $263M AUM 50.07% 1-Year Est. Return
GC
GatePass Capital Independence, Ohio $263M AUM 39.37% 1-Year Est. Return

Krensavage Asset Management's Q3 2015 Portfolio in Review

As of Q3 2015, Krensavage Asset Management held 23 positions worth $276M, up 4.2% from $265M the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Krensavage Asset Management deployed $51.5M of net new capital in Q3 2015, opening 1 new position and adding to 19 existing holdings. Its largest new stake was BAXALTA INC COM STK (DE): 721,800 shares worth $22.7M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 94% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Sucampo Pharmaceuticals, Inc., an estimated $10.1M trimmed.

  • Krensavage Asset Management's largest Q3 2015 buy was BAXALTA INC COM STK (DE): 721,800 shares worth $22.7M.
  • Krensavage Asset Management added most to United Therapeutics in Q3 2015, an estimated $8.13M increase.
  • Krensavage Asset Management's biggest Q3 2015 reduction was Sucampo Pharmaceuticals, Inc., cutting an estimated $10.1M.
  • Krensavage Asset Management's ten largest holdings make up 70% of its $276M portfolio in Q3 2015.
  • Krensavage Asset Management opened 1 new position and closed 0 in Q3 2015.
  • Krensavage Asset Management's portfolio value rose 4.2% quarter-over-quarter to $276M.

Based on Krensavage Asset Management's 13F filing for Q3 2015, filed 13 Nov 2015.